NCAM1 and triple-negative breast carcinoma: We suggest that the NCAM1+ subtype is likely equivalent to the one recently found by Wu et al (2019) who discovered that a Vδ1+ IL17AnegIFNγ+ subtype was in association with better overall survival of triple-negative breast cancer patients.